CONTENTS

1. Apremilast in Psoriasis–A Prospective Real-world Study 1
2. Comparative Effectiveness of Abatacept, Apremilast, Secukinumab and Ustekinumab Treatment of Psoriatic Arthritis: A Systematic Review and Network Meta-analysis 2
3. Management of Common Side Effects of Apremilast 3
4. Apremilast for the Treatment of Moderate-to-Severe Palmoplantar Psoriasis: Results from a Double-Blind, Placebo-Controlled, Randomized Study 5
5. Long-term Safety and Tolerability of Apremilast in Patients with Psoriasis: Pooled Safety Analysis for ≥156 Weeks from 2 Phase 3, Randomized Controlled Trials (ESTEEM 1 and 2) 6
6. Secukinumab and Apremilast Combination Therapy for Recalcitrant Psoriasis 8
7. Apremilast: A Review in Psoriasis and Psoriatic Arthritis 9
8. Serum Squamous Cell Carcinoma Antigen in Psoriasis: A Potential Quantitative Biomarker for Disease Severity 10
9. Long-term Real-life Safety Profile and Effectiveness of Fumaric Acid Esters in Psoriasis Patients: A Single-Centre, Retrospective, Observational Study 11
10. Association between Circulating 25-hydroxyvitamin D Levels and Psoriasis, and Correlation with Disease Severity: A Meta-analysis 13
11. Maintenance of Skin Clearance with Ixekizumab Treatment of Psoriasis: Three-Year Results from the UNCOVER-3 Study 14
12. Psoriasis and the Risk of Diabetes: A Prospective Population-based Cohort Study 16
13. Psoriatic Patients with Chronic Viral Hepatitis do not have an Increased Risk of Liver Cirrhosis Despite Long-term Methotrexate Use: Real-world Data from a Nationwide Cohort Study in Taiwan 17
14. Reporting of Outcomes in Randomized Controlled Trials on Nail Psoriasis: A Systematic Review 18
15. Risk of Cancer in Patients with Psoriasis on Biological Therapies: A Systematic Review 19
16. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis 20

17. Secukinumab Treatment of Moderate to Severe Plaque Psoriasis in Routine Clinical Care: Real-life Data of Prior and Concomitant Use of Psoriasis Treatments from the PROSPECT Study 21

18. Serum Levels of Psoriasin (S100A7) and Koebnerisin (S100A15) as Potential Markers of Atherosclerosis in Patients with Psoriasis 22

19. Simulating the Life Course of Psoriasis Patients: The Interplay between Therapy Intervention and Marital Status 23

20. Smoking Paradox in the Development of Psoriatic Arthritis among Patients with Psoriasis: A Population-based Study 24

21. Stricturing and Fistulizing Crohn's Disease is Associated with Anti-tumor Necrosis Factor-induced Psoriasis in Patients with Inflammatory Bowel Disease 25

22. Studying the Effect of Systemic and Biological Drugs on Intima-Media Thickness in Patients Suffering from Moderate and Severe Psoriasis 26

23. Systemic Immune Mechanisms in Atopic Dermatitis and Psoriasis with Implications for Treatment 27

24. The Akkermansia-muciniphila is a gut Microbiota Signature in Psoriasis 28

25. Topical Corticosteroid Concerns among Parents of Children with Psoriasis Versus Atopic Dermatitis: A French Multicentre Cross-sectional Study 30

26. Fumaric Acid Esters in Combination with a 6-week Course of Narrowband Ultraviolet B Provides an Accelerated Response Compared with Fumaric Acid Esters Monotherapy in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized Prospective Clinical Study 31

27. Association between Obesity and Pediatric Psoriasis 32

28. Real-world Health Outcomes in Adults with Moderate-to-Severe Psoriasis in the United States: A Population Study Using Electronic Health Records to Examine Patient-perceived Treatment Effectiveness, Medication Use, and Healthcare Resource Utilization 33

29. Dietary Recommendations for Adults with Psoriasis or Psoriatic Arthritis from the Medical Board of the National Psoriasis Foundation: A Systematic Review 34

30. Turmeric Tonic as a Treatment in Scalp Psoriasis: A Randomized Placebo-control Clinical Trial 35

31. Prevalence of Psoriatic Arthritis in Patients with Psoriasis: A Systematic Review and Meta-analysis of Observational and Clinical Studies 37

32. A Multicenter, Prospective, Observational Study Examining the Impact of Risk Factors, Such as BMI and Waist Circumference, on Quality of Life Improvement and Clinical Response in Moderate-to-Severe Plaque-type Psoriasis Patients Treated with Infliximab in Routine Care Settings of Greece 38

33. A Multidimensional Assessment of the Burden of Psoriasis: Results from a Multinational Dermatologist and Patient Survey 39

34. A Systematic Review and Meta-analysis of Efficacy and Safety of Novel Interleukin Inhibitors in the Management of Psoriatic Arthritis 41

35. Analysis of Anti-tumour Necrosis Factor-induced Skin Lesions Reveals Strong T Helper 1 Activation with some Distinct Immunological Characteristics 42

36. Association between Circulating Prolactin Levels and Psoriasis and Its Correlation with Disease Severity: A Meta-analysis 43

37. Burden of Chronic Urticaria Relative to Psoriasis in Five European Countries 44

38. Biologics Combined with Conventional Systemic Agents or Phototherapy for the Treatment of Psoriasis: Real-life Data from PSONET Registries 45

39. Carboxytherapy for Treatment of Localized Chronic Plaque Psoriasis: Clinical and Histopathologic Evaluation 47

40. Comparison of Effectiveness and Safety of Excimer Lamp Vs Topical Calcipotriol-clobetasol Propionate Combination in the Treatment of Palmoplantar Psoriasis 48

41. Comparison of Indirubin Concentrations in *Indigo naturalis* Ointment for Psoriasis Treatment: A Randomized, Double-blind, Dosage-controlled Trial 49

42. Efficacy and Safety of Tofacitinib for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-analysis of Randomized Controlled Trials 51

43. Efficacy and Safety of Guselkumab in Patients with Psoriasis Who Have an Inadequate Response to Ustekinumab: Results of the Randomized, Double-blind, Phase III NAVIGATE Trial 52

44. Effect of Secukinumab on Quality of Life and Psoriasis-related Symptoms: A Comparative Analysis Versus Ustekinumab from the CLEAR 52-week Study 53

45. Differential Effects of Secukinumab vs. Ustekinumab for Treatment of Psoriasis on Quality of Life, Work Productivity and Activity Impairment: A Structural Equation Modelling Analysis 55

46. Glucose Transporter-1 (GLUT-1) Expression in Psoriasis: Correlation with Disease Severity 56

47. Exposure to Biological Therapies during Conception and Pregnancy: A Systematic Review 57

48. Higher Coronary Plaque Burden in Psoriatic Arthritis is Independent of Metabolic Syndrome and Associated with Underlying Disease Severity 59

49. Increased Levels of Lipocalin 2 in Palmoplantar Pustular Psoriasis 60

50. Ixekizumab Treatment for Psoriasis: Integrated Efficacy Analysis of Three Double-blinded, Controlled Studies (UNCOVER-1, UNCOVER-2, UNCOVER-3) 61

51. Long-term Clinical Efficacy and Safety of Secukinumab for Japanese Patients with Psoriasis: A Single-center Experience 62

52. Matching-adjusted Indirect Comparison of Efficacy in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab vs. Secukinumab 64

53. Metabolic Syndrome in Psoriatic Arthritis: The Interplay with Cutaneous Involvement. Evidences from Literature and a Recent Cross-sectional Study 65

54. IL-17C: A Unique Epithelial Cytokine with Potential for Targeting across the Spectrum of Atopic Dermatitis and Psoriasis 66

55. Patient-reported Symptoms and Signs of Moderate-to-Severe Psoriasis Treated with Guselkumab or Adalimumab: Results from the Randomized VOYAGE 1 trial 67

56. Effects of Treatment for Psoriasis on Circulating Levels of Leptin, Adiponectin and Resistin: A Systematic Review and Meta-analysis 68

57. Subcutaneous Methotrexate in Patients with Moderate-to-Severe Psoriasis: A Critical Appraisal 69

58. Management of Psoriasis in Patients with Inflammatory Bowel Disease: From the Medical Board of the National Psoriasis Foundation 71

59. Interleukin 17, Inflammation, and Cardiovascular Risk in Patients with Psoriasis 72

60. Levels of miR-31 and its Target Genes in Dermal Mesenchymal Cells of Patients with Psoriasis 73

61. Serum Elafin as a Potential Inflammatory Marker in Psoriasis 74

62. Sex Hormones, Erectile Dysfunction, and Psoriasis; A Bad Friendship! 75

63. Psoriasis and Suicidality: A Systematic Review and Meta-analysis 76

64. Psoriasis and Vitiligo are Close Relatives 77

65. Psoriasis Is Associated with Risk of Obstructive Sleep Apnea Independently from Metabolic Parameters and Other Comorbidities: A Large Hospital-based Case-control Study 78

66. Psoriasis, Fracture Risk and Bone Mineral Density: The HUNT Study, Norway 80

67. Rate of Serious Infection in Patients Who Are Prescribed Systemic Biologic or Nonbiologic Agents for Psoriasis: A Large, Single Center, Retrospective, Observational Cohort Study 81

68. Review of Phase III Trial Data on IL-23 Inhibitors Tildrakizumab and Guselkumab for Psoriasis 82

69. Risk for Hepatitis B and C Virus Reactivation in Patients with Psoriasis on Biologic Therapies: A Retrospective Cohort Study and Systematic Review of the Literature 83

70. Risk of Developing Psoriasis in Patients with Schizophrenia: A Nationwide Retrospective Cohort Study 84

71. Risk of Malignancy with Systemic Psoriasis Treatment in the Psoriasis Longitudinal Assessment Registry 85

72. Risk of Suicidality in People with Psoriasis: A Systematic Review and Meta-analysis of Cohort Studies 86

73. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis 87

74. Severity of Psoriasis Differs between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients 89

75. Silencing of Homeobox A5 Gene in the Stratum Corneum of Psoriasis 90

76. Skin-infiltrating, Interleukin-22-producing T cells Differentiate Pediatric Psoriasis from Adult Psoriasis 91

77. Spotlight on Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: Design, Development, and Use in Therapy 92

78. Systematic Review and Meta-analysis of the Association between Psoriasis and Metabolic Syndrome 93

79. Th17 Inhibitors in Active Psoriatic Arthritis: A Systematic Review and Meta-analysis of Randomized Controlled Clinical Trials 94

80. The Acitretin and Methotrexate Combination Therapy for Psoriasis Vulgaris Achieves Higher Effectiveness and Less Liver Fibrosis 95

81. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review 96

82. The Metabolic Analysis of Psoriasis Identifies the Associated Metabolites while Providing Computational Models for the Monitoring of the Disease 98

83. The Relationship between Duration of Psoriasis, Vascular Inflammation and Cardiovascular Events 99

84. The Relevance of Serum Vitamin D in Psoriasis: A Review 100

85. The Risk of Malignancy among Biologic-naïve Pediatric Psoriasis Patients: A Retrospective Cohort Study in a US Claims Database 101

86. Risk of Venous Thromboembolism in Patients with Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis: A General Population-based Cohort Study 102

87. A 2-Year Observational Study on Treatment Targets in Psoriatic Arthritis Patients Treated with TNF Inhibitors 103

88. Anthralin Modulates the Expression Pattern of Cytokeratins and Antimicrobial Peptides by Psoriatic Keratinocytes 105

89. Association of Psoriasis and Psoriatic Arthritis with Osteoporosis and Pathological Fractures 106

90. Associations between Body Mass Index and Severity of Psoriasis 107

91. Bariatric Surgery and the Incidence of Psoriasis and Psoriatic Arthritis in the Swedish Obese Subjects Study 108

92. Atorvastatin as Adjunctive Therapy for Chronic Plaque Type Psoriasis versus Betamethasone Valerate Alone: A Randomized, Double-blind, Placebo-controlled Trial 109

93. British Association of Dermatologists Guidelines for Biologic Therapy for Psoriasis 2017 110

94. Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-life Data 112

95. Chemerin as a Marker of Subclinical Cardiac Involvement in Psoriatic Patients 113

96. Clinical Efficacy and IL-17 Targeting Mechanism of *Indigo naturalis* as a Topical Agent in Moderate Psoriasis 114

97. Comparative Evaluation of Efficacy and Safety of Calcipotriol versus Tacalcitol Ointment, Both in Combination with NBUVB Phototherapy in the Treatment of Stable Plaque Psoriasis 115

98. Comparison of Ixekizumab with Ustekinumab in Moderate-to-Severe Psoriasis: 24-Week Results from IXORA-S, a Phase III Study 117

99. Comparison of Phenotype, Comorbidities, Therapy and Adverse Events between Psoriatic Patients with and without Psoriatic Arthritis. Biobadaderm Registry 118

100. Depression and Suicidality in Psoriasis: Review of the Literature Including the Cytokine Theory of Depression 120

101. Development of Paradoxical Inflammatory Disorders During Treatment of Psoriasis with TNF Inhibitors: A Review of Published Cases 121

102. Effects of Wannachawee Recipe with Antipsoriatic Activity on Suppressing Inflammatory Cytokine Production in HaCaT Human Keratinocytes 122

103. Effectiveness of Lipid-lowering Statin Therapy in Patients with and without Psoriasis 124

104. Effects of Nanoparticles with Hydrotropic Nicotinamide on Tacrolimus: Permeability through Psoriatic Skin and Antipsoriatic and Antiproliferative Activities 125

105. Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials 126

106. Effectiveness and Safety of Secukinumab in 69 Patients with Moderate to Severe Plaque Psoriasis: A Retrospective Multicenter Study 127

107. Diagnosis and Management of Psoriasis 129

108. Early Relapse of Psoriasis after Stopping Brodalumab: A Retrospective Cohort Study in 77 Patients 130

109. Emerging Targeted Therapies for Plaque Psoriasis – Impact of Ixekizumab 131

110. Infections from Seven Clinical Trials of Ixekizumab, an Anti-interleukin-17A Monoclonal Antibody, in Patients with Moderate-to-Severe Psoriasis 133

111. High Rate of Systemic Corticosteroid Prescription among Outpatient Visits for Psoriasis: A Population-based Epidemiological Study Using the Korean National Health Insurance Database 134

112. Hyperuricemia Is an Independent Risk Factor for Psoriatic Arthritis in Psoriatic Patients 135

113. How Is Disease Severity Associated with Quality of Life in Psoriasis Patients? Evidence from a Longitudinal Population-based Study in Sweden 137

114. Influence of TNF-alpha Inhibitors and Fumaric Acid Esters on Male Fertility in Psoriasis Patients 138

115. Interval between Onset of Psoriasis and Psoriatic Arthritis Comparing the UK Clinical Practice Research Datalink with a Hospital-based Cohort 139

116. Increased Prevalence of HCV and Hepatic Decompensation in Adults with Psoriasis: A Population-based Study in the United Kingdom 141

117. Evaluation of Adherence Predictors for the Treatment of Moderate to Severe Psoriasis with Biologics: The Importance of Physician-patient Interaction and Communication 142

118. Exploration of Candidate Biomarkers for Human Psoriasis Based on Gas Chromatography-mass Spectrometry Serum Metabolomics 143

119. Increased Frequencies of Basophils, Type 2 Innate Lymphoid Cells and Th2 Cells in Skin of Patients with Atopic Dermatitis but not Psoriasis 145

120. Initiation, Switching, and Cessation of Psoriasis Treatments among Patients with Moderate to Severe Psoriasis in the United States 146

121. Limited Presence of IL-22 Binding Protein, a Natural IL-22 Inhibitor, Strengthens Psoriatic Skin Inflammation 147

122. Long-term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-year Interim Analysis of the ESPRIT Registry 148

123. Lymphopenia and CD4+/CD8+ Cell Reduction under Fumaric Acid Esters 149

124. Magnetic Resonance Imaging in Psoriatic Arthritis: A Descriptive Study of Indications, Features and Effect on Treatment Change 150

125. Minimal Disease Activity in Patients with Psoriatic Arthritis Treated with Ustekinumab: Results from a 24-week Real-world Study 151

126. Evidence and Suggested Therapeutic Approach in Psoriasis of Difficult-to-Treat Areas: Palmoplantar Psoriasis, Nail Psoriasis, Scalp Psoriasis, and Intertriginous Psoriasis 152

127. Topical Therapies for Psoriasis 154

128. Psoriasis and Comorbid Diseases: Implications for Management 156

129. Translating Psoriasis Guidelines into Practice: Important Gaps Revealed 158